Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its binding ability in a functional ELISA. When human Cytochrome c is coated at 1 μg/mL (100 μL/well), the concentration of Recombinant Human LRG1 that produces 50% of the optimal binding response is 3-15 ng/mL.
Source
Human embryonic kidney cell, HEK293-derived Val36-Gln347, with a C-terminal 6-His tag
Accession #
N-terminal Sequence
AnalysisVal36
Predicted Molecular Mass
35.2 kDa
SDS-PAGE
40-60 kDa, reducing conditions
7890-LR |
| |
Formulation Lyophilized from a 0.2 μm filtered solution in PBS and Trehalose. | ||
Reconstitution Reconstitute at 200 μg/mL in PBS. | ||
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: LRG1
LRG1 (leucine-rich alpha -2-glycoprotein 1) is an approximately 50 kDa secreted glycoprotein present in the plasma and other body fluids (1‑4). The human LRG1 cDNA encodes 347 amino acids (aa) that include a 35 aa signal sequence, eight leucine‑rich repeats (LRR), and an LRRCT (LRR C‑terminal) domain (1). Mature human LRG1 shares 66%, 63%, 75% and 72% aa sequence identity with mouse, rat, canine and porcine LRG1, respectively. LRG1 is up‑regulated during differentiation of neutrophils and present with myeloperoxidase in primary neutrophilic granules (1, 2). It can be produced by hepatocytes as an acute phase protein (5). LRG1 can interact directly with Cytochrome c, and is thought to act as a survival factor for lymphocytes in the presence of extracellular Cytochrome c (3, 6). Serum or plasma LRG1 is reported to be elevated in toxic shock syndrome, cardiac damage (produced by cardiomyocytes and correlating with BNP), autoimmune syndromes such as rheumatoid arthritis and Crohn’s disease, and some cancers such as those in the ovary and biliary tract (4, 7‑10). It is elevated in coronary sinus fluid during ventricular dysfunction and heart failure, and in peritoneal fluid of patients with uterine lyomyomas (8, 11).
References:
O’Donnell, L.C. et al. (2002) J. Leukoc. Biol. 72:478.
Ai, J. et al. (2008) J. Leukoc. Biol. 83:1277.
Cummings, C. et al. (2006) Apoptosis 11:1121.
Weivoda, S. et al. (2008) J. Immunol. Methods 336:22.
Shirai, R. et al. (2009) Biochem. Biophys. Res. Commun. 382:776.
Codina, R. et al. (2010) Apoptosis 15:139.
Serada, S. et al. (2010) Ann. Rheum. Dis. 69:770.
Watson, C.J. et al. (2011) Circ. Heart Fail. 4:188.
Andersen, J.D. et al. (2010) J. Ovarian Res. 3:21.
Sandanayake, N.S. et al. (2011) Br. J. Cancer 105:1370.
Ferrero, S. et al. (2009) Arch. Gynecol. Obstet. 279:365.
Long Name:
Leucine-rich alpha-2-glycoprotein 1
Entrez Gene IDs:
116844 (Human); 76905 (Mouse); 367455 (Rat)
Alternate Names:
1300008B03Rik; 2310031E04Rik; HMFT1766; leucine-rich alpha-2-glycoprotein 1; leucine-rich alpha-2-glycoprotein; LRG1; LRGleucine rich alpha 2 glycoprotein
